All News

PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

d Meral K. El Ramahi, MD, FACP, FACR

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34

Links:

Dr. John Cush RheumNow ( View Tweet)
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate ) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more. https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR

Links:

Dr. John Cush RheumNow ( View Tweet)
Which patients with psoriasis are at risk to develop PsA? The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum. https://t.co/5sj5HSnke3 https://t.co/NwoIoDH5rC

Links:

Dr. John Cush RheumNow ( View Tweet)
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

d Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

d Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
EULAR,poster

EULAR 2021 – Day 1 Report

d Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq
k dao KDAO2011 ( View Tweet)

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Paul Studenic Stiddyo ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Eric Dein ejdein1 ( View Tweet)

New download available! Difficult RA Defined https://t.co/6WGMEiwiUk https://t.co/VTCm4cuyRe

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Myth Busters (5.21.2021)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
Psoriasis, arms, PsA

IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis

d Jack Cush, MD

Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death. 

Read Article
Increased Methotrexate Liver Disease in Psoriasis https://t.co/sEZajDIkSz

Links:

Dr. John Cush RheumNow ( View Tweet)

RNL, over, microphone

RheumNow Live 2021 Now Available for All

d Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.